Algae.Tec opens new facility in Australia

Updated on 16 August 2012

The opening of the advanced engineered algae to biofuels facility is a significant step at a time when carbon tax is emerging as a major issue in Australia

algae-tec-biofuel

The facility is connected into the Manildra Group waste carbon dioxide, which is used in the algae growth process

Singapore: Algae.Tec, an advanced algae to biofuels company, has opened a new facility Shoalhaven One at Nowra, south of Sydney in Australia. The facility, first-of-its-kind in the country, is an advanced engineered algae to biofuels facility.

The facility will give the company a significant edge in business at a time when carbon tax is a hotly debated topic in Australia. Algae.Tec has a high-yield, enclosed and scalable algae growth and harvesting system, the McConchie-Stroud System. The facility is connected into the Manildra Group waste carbon dioxide, which is used in the algae growth process.

Algae.Tec Executive Chairman Mr Roger Stroud said this offered NSW and Australia energy security at a time when traditional fossil fuel companies were leaving the local market. "Algae.Tec offers the promise of home grown transport fuels (aviation and diesel), which is the number one energy security priority for countries like the USA and increasingly Australia," he said.

Founded in 2007, the company produces advanced renewable oil from algae. Australia is stressing on a carbon pricing scheme to reduce its carbon footprint. With the focus on clean energy, Algae.Tec technology to grow non-GMO algae on an industrial scale, and produce biofuels that replace predominantly imported fossil fuels can be the answer.

The technology has demonstrated exceptional performance in productivity, product yield, carbon dioxide sequestration, and production unit footprint requirements versus agricultural crops and other competitive algae processes in the industry.

 

Previous 1

Leave a Reply

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X